This is not the latest version of this item. The latest version can be found here.
Opportunities, Barriers, and a Strategy for Overcoming Translational Challenges to Therapeutic Nucleic Acid Nanotechnology
Name
nihms-1616054.pdf
Description
Accepted version
Size
636.13 KB
Format
Adobe PDF
Checksum (MD5)
144b3a2da70f9c28aeeeb3f7819d5701
Author(s)
Afonin, Kirill A
Dobrovolskaia, Marina A
Church, George
Bathe, Mark
Date Issued
2020
Journal
ACS Nano
Publisher
American Chemical Society (ACS)
Version
Author's final manuscript
Abstract
Recent clinical successes using therapeutic nucleic acids (TNAs) have accelerated the transition of nucleic acid nanotechnology toward therapeutic applications. Significant progress in the development, production, and characterization of nucleic acid nanomaterials and nucleic acid nanoparticles (NANPs), as well as abundant proof-of-concept data, are paving the way toward biomedical applications of these materials. This recent progress has catalyzed the development of new strategies for biosensing, imaging, drug delivery, and immunotherapies with previously unrecognized opportunities and identified some barriers that may impede the broader clinical translation of NANP technologies. A recent workshop sponsored by the Kavli Foundation and the Materials Research Society discussed the future directions and current challenges for the development of therapeutic nucleic acid nanotechnology. Herein, we communicate discussions on the opportunities, barriers, and strategies for realizing the clinical grand challenge of TNA nanotechnology, with a focus on ways to overcome barriers to advance NANPs to the clinic.
Terms of Use
Creative Commons Attribution-Noncommercial-Share Alike
Persistent DSpace Link
DOI of Published Version
10.1021/ACSNANO.0C04753
